Table 1. Gene Ontology Analysis of enriched transcripts at sequential stages of differentiation.
| Category | Term | Benjamini |
||
|---|---|---|---|---|
| Count | % | Corrected P-value | ||
| Day 5 (Enriched transcripts in M+ vs M−, FC > 1.5, P < 0.05) | ||||
| PANTHER_BP | BP00193:Developmental processes | 89 | 20,60 | 1,35E-06 |
| PANTHER_BP | BP00102:Signal transduction | 108 | 25,00 | 0,011389832 |
| PANTHER_BP | BP00274:Cell communication | 47 | 10,88 | 0,018208241 |
| PANTHER_BP | BP00248:Mesoderm development | 27 | 6,25 | 0,020433632 |
| PANTHER_BP | BP00246:Ectoderm development | 31 | 7,18 | 0,016956308 |
| PANTHER_BP | BP00199:Neurogenesis | 27 | 6,25 | 0,032211571 |
| PANTHER_MF | MF00178:Extracellular matrix | 27 | 6,25 | 3,52E-05 |
| PANTHER_MF | MF00179:Extracellular matrix structural protein | 11 | 2,55 | 0,001599702 |
| Day 7 (Enriched transcripts in M+ vs M−, FC > 1.5, P < 0.05) | ||||
| PANTHER_BP | BP00193:Developmental processes | 38 | 24,36 | 0,002291487 |
| PANTHER_BP | BP00124:Cell adhesion | 16 | 10,26 | 0,015033261 |
| PANTHER_BP | BP00281:Oncogenesis | 12 | 7,69 | 0,059284076 |
| PANTHER_BP | BP00274:Cell communication | 22 | 14,10 | 0,046309515 |
| PANTHER_BP | BP00102:Signal transduction | 43 | 27,56 | 0,187888803 |
| PANTHER_BP | BP00122:Ligand-mediated signaling | 9 | 5,77 | 0,425197991 |
| PANTHER_BP | BP00071:Proteolysis | 15 | 9,62 | 0,405883178 |
| PANTHER_BP | BP00109:Receptor protein serine/threonine kinase signaling pathway | 3 | 1,92 | 0,531826987 |
| PANTHER_BP | BP00248:Mesoderm development | 10 | 6,41 | 0,535902255 |
| PANTHER_BP | BP00103:Cell surface receptor mediated signal transduction | 21 | 13,46 | 0,653573879 |
| PANTHER_BP | BP00267:Homeostasis | 5 | 3,21 | 0,667475861 |
| PANTHER_MF | MF00178:Extracellular matrix | 18 | 11,54 | 1,59E-06 |
| PANTHER_MF | MF00282:Aspartic protease | 4 | 2,56 | 0,035633978 |
| PANTHER_MF | MF00179:Extracellular matrix structural protein | 6 | 3,85 | 0,041276498 |
| Day 10 (Enriched transcripts in M+ vs M−, FC > 1.5, P < 0.05) | ||||
| PANTHER_BP | BP00173:Muscle contraction | 38 | 5,65 | 2,02E-14 |
| PANTHER_BP | BP00250:Muscle development | 25 | 3,71 | 9,55E-08 |
| PANTHER_BP | BP00248:Mesoderm development | 51 | 7,58 | 1,36E-06 |
| PANTHER_BP | BP00193:Developmental processes | 122 | 18,13 | 1,58E-04 |
| PANTHER_BP | BP00251:Heart development | 10 | 1,49 | 0,004440264 |
| PANTHER_BP | BP00285:Cell structure and motility | 65 | 9,66 | 0,019756301 |
| PANTHER_BP_ALL | BP00287:Cell motility | 27 | 4,01 | 0,018914324 |
| PANTHER_MF | MF00261:Actin binding cytoskeletal protein | 48 | 7,13 | 1,83E-11 |
| PANTHER_MF | MF00091:Cytoskeletal protein | 63 | 9,36 | 6,27E-06 |
| PANTHER_MF | MF00178:Extracellular matrix | 34 | 5,05 | 2,34E-04 |
| PANTHER_MF | MF00230:Actin binding motor protein | 9 | 1,34 | 0,024317475 |
| Day 14 (Enriched transcripts in M+ vs M−, FC > 1.5, P < 0.05) | ||||
| PANTHER_BP | BP00173:Muscle contraction | 35 | 0,41 | 1,00E-10 |
| PANTHER_BP | BP00250:Muscle development | 25 | 0,29 | 6,18E-07 |
| PANTHER_BP | BP00248:Mesoderm development | 55 | 0,64 | 6,46E-07 |
| PANTHER_BP | BP00193:Developmental processes | 141 | 1,65 | 9,67E-07 |
| PANTHER_BP | BP00285:Cell structure and motility | 80 | 0,94 | 8,87E-05 |
| PANTHER_BP | BP00286:Cell structure | 50 | 0,59 | 0,002674421 |
| PANTHER_BP | BP00251:Heart development | 10 | 0,12 | 0,006537938 |
| PANTHER_BP | BP00287:Cell motility | 30 | 0,35 | 0,006541566 |
| PANTHER_BP | BP00109:Receptor protein serine/threonine kinase signaling pathway | 8 | 0,09 | 0,032075749 |
| PANTHER_MF | MF00261:Actin binding cytoskeletal protein | 52 | 0,61 | 3,25E-12 |
| PANTHER_MF | MF00091:Cytoskeletal protein | 71 | 0,83 | 3,81E-07 |
| PANTHER_MF | MF00178:Extracellular matrix | 34 | 0,40 | 0,001924022 |
| PANTHER_MF | MF00188:Select calcium binding protein | 26 | 0,30 | 0,007733675 |
| PANTHER_MF | MF00179:Extracellular matrix structural protein | 13 | 0,15 | 0,008110282 |
| PANTHER_MF | MF00230:Actin binding motor protein | 9 | 0,11 | 0,031006045 |
Differentially expressed genes in the MESP1-mCherry positive derived cardiac populations were selected on a FC > 1.5 fold difference with their MESP1-mCherry negative counterpart, and a P-value < 0.05, n = 3. GO-analysis was performed using the Panther Classification System. Multiple-GO-term correction was performed using the Benjamini-Yekutieli method. GO-terms hold a corrected p-value < 0.05.